BNP Paribas Asset Management
CNTA

BNP Paribas Asset Management’s Centessa Pharmaceuticals CNTA Stock Holding History

BNP Paribas Asset Management’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-702,254
Closed -$27.9M – 2276
2026
Q1 		$27.9M Buy
+702,254
New +$18M 0.03% 476

BNP Paribas Asset Management's CNTA Position: Q2 2026 in Review

BNP Paribas Asset Management sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 702,254 shares — an estimated $27.9M sold.

BNP Paribas Asset Management first reported a position in CNTA in Q1 2026 and held it in 1 quarter. The position peaked at $27.9M in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

  • BNP Paribas Asset Management reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • BNP Paribas Asset Management sold 702,254 Centessa Pharmaceuticals shares in Q2 2026, an estimated $27.9M.
  • BNP Paribas Asset Management first reported a position in Centessa Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • BNP Paribas Asset Management's Centessa Pharmaceuticals position peaked at $27.9M in Q1 2026.
  • 0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.